Pluristem Therapeutics logo

PSTI Pluristem Therapeutics

Pluristem Therapeutics, Inc. engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. It focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Healthcare Biotechnology CIK: 1158780 Auditor raised Going Concern issues

Transaction DateRecipientSharesTypePriceValue
Jodie Insights Rating